Hoth Therapeutics (HOTH) Prices 8.24M Share Offering at $0.85/sh

Hoth Therapeutics, Inc. (NASDAQ: HOTH) today announced the pricing of its underwritten public offering of 8,235,294 shares of common stock (the "Common Stock") at a public offering price of $0.85 per share, priced at-the-market under Nasdaq rules, for aggregate gross proceeds of approximately $7.0 million, prior to deducting underwriting discounts, commissions, and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,235,294 shares of Common Stock at the public offering price per share, less the underwriting discounts and commissions, to cover over-allotments, if any.

The offering is expected to close on or about April 14, 2022, subject to satisfaction of customary closing conditions.

The Company intends to use the net proceeds from this offering for general corporate and working capital purposes.

EF Hutton, division of Benchmark Investments, LLC, is acting as sole book-running manager for the offering.

The proposed offering of the Common Stock described above is being offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-236887) filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on March 11, 2020, and the accompanying prospectus contained therein.

A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC's website at www.sec.gov. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website.

Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting EF Hutton, division of Benchmark Investments, LLC Attention: Syndicate Department, 590 Madison Avenue, 39th Floor, New York, NY 10022, by email at [email protected], or by telephone at (212) 404-7002.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement.

You May Also Be Interested In

• Singularity Future Technology closes $5M registered direct offering
• Aveanna selling stockholders launch 15M share secondary offering
• SEC accuses ex-BofA senior banker Satsky of insider trading - Bloomberg